|
|
Johnson and Johnson (JNJ) |
|
Price: $160.0100
$-0.25 
-0.156%
|
| Day's High:
| $160.41
| Week Perf:
| 1.07 %
|
| Day's Low: |
$ 157.82 |
30 Day Perf: |
-1.01 % |
| Volume (M): |
335 |
52 Wk High: |
$ 183.35 |
| Volume (M$): |
$ 53,577 |
52 Wk Avg: |
$166.83 |
| Open: |
$158.50 |
52 Wk Low: |
$150.11 |
|
|
| Market Capitalization (Millions $) |
416,906 |
| Shares
Outstanding (Millions) |
2,606 |
| Employees |
141,700 |
| Revenues (TTM) (Millions $) |
96,263 |
| Net Income (TTM) (Millions $) |
12,724 |
| Cash Flow (TTM) (Millions $) |
12,768 |
| Capital Exp. (TTM) (Millions $) |
4,265 |
Johnson And Johnson
Johnson & Johnson, employing approximately 110,600 people worldwide, is engaged
in the manufacture and sale of a broad range of products in the health care field.
Through over 200 operating companies, it conducts business in virtually all countries
of the world. Johnson & Johnsons primary interest, both historically and
currently, has been in products related to human health and well-being. Johnson
& Johnson was organized in the State of New Jersey in 1887.
Johnson & Johnson is organized on the principle of decentralized management.
The Executive Committee of Johnson & Johnson is the principal management
group responsible for the operations and allocation of the resources of the
Company. This Committee oversees and coordinates the activities of the Consumer,
Pharmaceutical and Medical Devices and Diagnostics business segments. Each subsidiary
within the business segments is, with some exceptions, managed by citizens of
the country in which it is located.
Johnson & Johnsons worldwide business is divided into three segments:
Consumer, Pharmaceutical and Medical Devices and Diagnostics.
CONSUMER
The Consumer segment manufactures and markets a broad range of products used
in the baby and child care, skin care, oral and wound care and womens health
care fields, as well as nutritional and over-the-counter pharmaceutical products.
PHARMACEUTICAL
The Pharmaceutical segments principal worldwide franchises are in the antifungal,
anti-infective, cardiovascular, contraceptive, dermatology, gastrointestinal,
hematology, immunology, neurology, oncology, pain management, psychotropic (central
nervous system) and urology fields.
MEDICAL DEVICES AND DIAGNOSTICS
The Medical Devices and Diagnostics segment includes a broad range of products
used by or under the direction of physicians, nurses, therapists, hospitals,
diagnostic laboratories and clinics.
The international business of Johnson & Johnson is conducted by subsidiaries
located in 56 countries outside the United States, which are selling products
in virtually all countries throughout the world.
COMPETITION
In all their product lines, Johnson & Johnson companies compete with companies
both large and small, located in the United States and abroad. Competition is
strong in all lines without regard to the number and size of the competing companies
involved. Competition in research, involving the development of new products
and processes and the improvement of existing products and processes, is particularly
significant and results from time to time in product and process obsolescence.
The development of new and improved products is important to Johnson & Johnsons
success in all areas of its business.
Company Address: One Johnson & Johnson Plaza New Brunswick 8933 NJ
Company Phone Number: 524-0400 Stock Exchange / Ticker: NYSE JNJ
| JNJ is expected to report next financial results on July 28, 2023. |
Next quarterly dividend pay out on September 08, 2023. |
|
|
|
Customers Net Income grew by |
JNJ's Customers Net Profit Margin fell to |
5.76 % |
4.25 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Aridis Pharmaceuticals Inc
Investors in Aridis Pharmaceuticals Inc. (ARDS) are in for a rough ride as recent financial results suggest that the company is not in a good financial position. In the fiscal timeframe closing March 31, 2023, the company reported a per-share loss of $-0.22 - a stark contrast to positive earnings experienced by other pharmaceutical companies in the same period.
The decrease in turnover resulted in fading revenue, leading to a larger shortfall. ARDS's revenue dropped by a staggering 8.846% to $1.08 million YoY. This decrease in revenue is alarming as it suggests that there are underlying issues that the company is struggling to address. Revenue is the lifeblood of businesses, and the fact that ARDS's revenue has taken such a significant hit speaks volumes about the company's struggles.
|
|
Lifecore Biomedical Inc
The pharmaceutical industry is a vital sector in the global economy. It is responsible for producing lifesaving drugs, vaccines, and other medical products that improve the lives and health of people globally. However, like any other industry, the pharmaceutical industry also faces its own set of challenges. These challenges range from regulatory and compliance issues to stiff competition and changing market dynamics.
Recently, one of the major pharmaceutical companies shared some good news. The company proclaimed record revenues of $27.6 million in the fiscal year ending February 26, 2023. This achievement is commendable, considering the challenges the pharmaceutical industry faces. However, another company in the sector, Lifecore Biomedical Inc, reported a net deficit of $-40.192 million in the same reporting season.
|
|
Globestar Therapeutics Corporation
The financial results for the Globestar Therapeutics Corporation (GSTC) for the January to March 31, 2023 reporting cycle have been released, and shareholders were not expecting any moderations at the top-line. However, it appears that they are paying a significant amount of attention to the company's operating shortfall, which was reported at $-0.142059 million during the same period. One positive aspect of this result is that it compares favorably to the performance of the second quarter of 2022, where the operating shortfall was significantly higher at $-0.66231 million. This appears to be a significant indicator for the company's course going forward.
For a company like GSTC, which is on an upward trajectory in terms of revenue generation, it becomes increasingly important to run cost-effectively in order to reach the next chapter of its growth. The good news is that there has been some alleviation on the bottom-line, as the diminishing returns have been cut from the same time frame a year prior. The fiscal span ending in the second quarter of 2023 saw a loss of $-0.150 million, which is lower than the loss of $-0.689 million reported in the same period in 2022. This is a major takeaway from the most recent financial results, which indicates that GSTC is moving in the right direction, albeit at a steady pace.
|
|
Q Biomed Inc
For the fourth quarter of 2022 earnings season Q Biomed Inc had turn a round to surplus by exhibiting earnings per share of $0.02 per share compare to $-0.08 a year before and earnings per share turned positive from $-0.03 per share from the prior financial reporting period. The revenue went down sharply by -88.053 % to $0.01 million from $0.10 million in the comparable financial reporting period a year before and sequentially Revenue Tumbled by -52.286 % from $0.03 million.
|
|
23andme Holding Co
23andme Holding Co Posts Mixed Q4 Results, Despite Lower Demand
23andme Holding Co, the popular genetic testing company, has released its latest earnings report for Q4 2023. In a disappointing development for investors, the company's revenue was hit hard by lower demand, leading to a vanishing revenue and higher deficit.
While the earnings report may have been mixed, there was some positive news to report. The company announced that it had been able to decrease its loss per share to $-0.13 per share, which may be seen as an encouraging sign to some investors. However, revenue decreased by -8.137% to $92.38 million, signifying that the company still has some way to go in order to generate more growth.
|
| Per Share |
Current |
| Earnings (TTM) |
4.78 $ |
| Revenues (TTM) |
36.95 $
|
| Cash Flow (TTM) |
4.9 $ |
| Cash |
9.45 $
|
| Book Value |
27.2 $
|
| Dividend (TTM) |
4.47 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
4.78 $
|
| Revenues (TTM) |
36.95 $ |
| Cash Flow (TTM) |
4.9 $ |
| Cash |
9.45 $
|
| Book Value |
27.2 $ |
| Dividend (TTM) |
4.47 $ |
|
|
| |
| PROCRIT |
|
Segment |
|
 |
of total Revenue |
| RISPERDAL |
|
Segment |
|
|
of total Revenue |
| REMICADE |
|
Segment |
|
|
of total Revenue |
| VELCADE |
|
Segment |
|
|
of total Revenue |
| CONCERTA |
|
Segment |
|
|
of total Revenue |
| INVEGA |
|
Segment |
|
|
of total Revenue |
| Other |
|
Segment |
|
|
of total Revenue |
| Total Pharmaceutical |
|
Segment |
|
|
of total Revenue |
| Med. Dev. & Diag. |
|
Segment |
|
|
of total Revenue |
| Nutritionals |
|
Segment |
|
|
of total Revenue |
| Skin Care |
|
Segment |
|
|
of total Revenue |
| Total Consumer |
|
Segment |
|
|
of total Revenue |
| |
|
|
0.96% 